PRECISION BIOSCIENCES INC (DTIL)
Health Care · Gene editing / genome editing therapeutics · NASDAQ
Precision BioSciences is a clinical-stage biotechnology company leveraging its proprietary ARCUS gene editing platform to develop potentially curative in vivo therapies for genetic and infectious diseases.
What PRECISION BIOSCIENCES INC does
Precision BioSciences is a clinical-stage gene editing company that develops in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. ARCUS is a natural homing endonuclease that enables precise gene editing through insertion, excision, and elimination. The company currently has two lead clinical programs: PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, plus a partnered program with iECURE for OTC deficiency.
Themes: gene editing / genome editing, in vivo therapy, hepatitis B treatment, Duchenne muscular dystrophy (DMD), mitochondrial disease, genetic diseases, rare genetic disorders
Fundamentals
- Price$8.85 as of 2026-08-21 close
- Market cap$244M as of 2026-08-21
- 1-year return+86.7% 2025-08-21 close $4.74 → 2026-08-21 close $8.85
- P/En/a negative earnings
- Net margin-96.7% as of 2026-08-24
- ROE-91.6% as of 2026-08-24
- Debt / equity0.49 as of 2026-08-24
- Revenue growth (YoY)-50.1% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)+10.9% SEC XBRL
- Beta1.33 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DTIL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PRECISION BIOSCIENCES INC looks technically
PRECISION BIOSCIENCES INC (DTIL) is trading 44.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 87 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-09, pushing above its recent trading range.
Trend
8
| Distance from the 200-day | it is trading 44.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +44.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.59 | $7.59 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.11 | $6.11 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 7.18. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 87 trading days ago — a "golden cross", a bullish long-term signal | 87 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 18.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 71.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($7.00 to $9.34) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 79.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.62 | $9.62 |
|---|---|---|
| From the 52-week high | it is 8.0% below its 52-week high (its highest price of the past year) | -8.0% |
| Above the 52-week low | it is 150.7% above its 52-week low (its lowest price of the past year) | +150.7% |
| Below the 52-week high | it is 8.0% below its highest point of the past year | 8.0% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-09, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $717.28 (set on 2019-12-09) | $717.28 |
| Given back of the 52-week move | over the past year its closes ranged ($3.57 to $9.28), and it has given back only a small part of its rise from last year’s low — 8% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.57 to $5.75. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.5% |
| From the all-time high | it is 98.8% below its all-time high | -98.8% |
| Nearest price level | it is trading 0.6% above a support level at $8.80 — a price it turned at twice since 2024-10-01, most recently on 2025-10-29. Since 2024-08-21 it has 16 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $3.53 (set on 2026-02-05) | $3.53 |
| Above the all-time low | it is 150.7% above its all-time low | +150.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4976 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4976 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.43 and $8.65 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.43 – $7.54 – $8.65 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 5.5 daily ranges above its 200-day average price (44.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.95× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.0% above the previous close 44 sessions ago and has not traded back through the level it left behind at 6.5 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.0% |
| Gap filled | a 6.3% gap down opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 4 sessions in a row, a +19.59% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.8 percentage points (the stock gained 16.1% while the market gained 2.3%) | +13.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.7 percentage points (the stock gained 23.8% while the market gained 3.1%) | +20.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 122.4 percentage points (the stock gained 133.5% while the market gained 11.1%) | +122.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 66.2 percentage points (the stock gained 86.7% while the market gained 20.5%) | +66.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.6% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.6% of the share price. | +6.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 31% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.75 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +31.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $7.94 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +11.4% |
Price levels it has turned at before
DTIL last closed at $8.85 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.80 | Support | 0.6% below the last close | turned there twice · 2024-10-01 to 2025-10-29 |
| $8.64 | Support | 2.3% below the last close | turned there twice · 2024-10-10 to 2026-05-13 |
| $9.17 | Resistance | 3.6% above the last close | turned there twice · 2024-10-21 to 2024-11-01 |
| $9.60 | Resistance | 8.5% above the last close | turned there twice · 2024-09-06 to 2026-07-07 |
| $7.95 | Support | 10.2% below the last close | turned there twice · 2024-10-31 to 2026-06-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $7.18.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$29.40 range $18.00 – $60.00; median $20.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DTIL
- Consensus EPS estimate-$0.8533 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: both lead programs (PBGENE-HBV and PBGENE-DMD) are in early-stage clinical trials with uncertain efficacy and safety outcomes that could delay or prevent regulatory approval","Competitive gene editing landscape: other genome editing technologies (CRISPR, base editors, prime editors) are advancing in parallel, with established competitors potentially capturing market share before ARCUS therapies reach commercialization","High cash burn and unprofitability: company is unprofitable with net margin of -96.73%, requiring significant continued funding to advance clinical programs through development and potential regulatory approval"]
What changed in the latest 10-Q
AI-assisted comparison of DTIL's 10-Q filed 2026-05-05 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05): 16 patients treated with 38 administrations across five cohorts in PBGENE-HBV Part 1 dose finding
- Newer filing (2026-05-05): Expected to share further clinical data from PBGENE-HBV at hepatitis-focused medical conferences throughout 2026, starting with EASL
- Newer filing (2026-05-05): Late-breaking poster for PBGENE-HBV accepted for EASL Congress 2026 on cccDNA elimination and inactivation
- Newer filing (2026-05-05): CTA approval to expand ELIMINATE-B into France and Romania in April 2026
- Newer filing (2026-05-05): IND clearance from FDA for PBGENE-DMD in early 2026
- Newer filing (2026-05-05): PBGENE-DMD received FDA Fast Track designation in March 2026
- Newer filing (2026-05-05): Arkansas Children's Hospital activated as first clinical trial site for FUNCTION-DMD in April 2026
- Newer filing (2026-05-05): Preclinical PBGENE-DMD data presented at Muscular Dystrophy Association Clinical & Scientific Conference 2026
- Newer filing (2026-05-05): iECURE expects to present clinical data from OTC-HOPE at ASGCT Annual Meeting in May 2026 with preliminary data from first three dose cohorts (n=7)
- Newer filing (2026-05-05): iECURE data includes decreased rate of hyperammonemic crises following ECUR-506 administration
- Newer filing (2026-05-05): One-year post-treatment data from first infant dosed showing complete clinical response with sustained discontinuation of standard-of-care therapies
- Newer filing (2026-05-05): Imugene received written FDA guidance on azer-cel registrational pathway
- Newer filing (2026-05-05): Azer-cel selected for oral presentation at 2026 American Society of Clinical Oncology Annual Meeting in May 2026
- Newer filing (2026-05-05): TG Therapeutics evaluating azer-cel in Phase 1 trial in progressive multiple sclerosis
- Newer filing (2026-05-05): Clinical milestone achievement under TG Therapeutics license agreement resulting in $7.5 million payment in March 2026
- Removed:
- Older filing (2025-11-03): Sentence about leveraging ARCUS platform to advance in vivo gene editing programs beyond gene knockouts
- Older filing (2025-11-03): Reference to ELIMINATE-B trial investigating PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level
- Older filing (2025-11-03): ELIMINATE-B recruiting patients in U.S., Moldova, Hong Kong, New Zealand and U.K.
- Older filing (2025-11-03): August 2025 announcement of Phase 1 safety and efficacy data for Cohorts 1 and 2
- Older filing (2025-11-03): September 2025 presentation at 6th International Coalition to Eliminate HBV Cure Symposium
- Older filing (2025-11-03): Commencement of dosing in Cohort 3 in third quarter 2025
- Older filing (2025-11-03): Late-breaking oral presentation at Liver Meeting 2025 on November 10, 2025
- Older filing (2025-11-03): Detailed background on DMD affecting approximately 15,000 patients in U.S. and lack of approved curative therapies
- Older filing (2025-11-03): FDA Rare Pediatric Disease designation in June 2025 and Orphan Drug Designation in July 2025 for PBGENE-DMD
- Older filing (2025-11-03): October 10, 2025 late-breaking poster presentation at World Muscle Society meeting with mouse model data on dystrophin expression and muscle function improvements
- Older filing (2025-11-03): Specific details on dystrophin detection at doses up to 1x10^14 vg/kg with improved expression at 9 months and maximum force output improvements
- Older filing (2025-11-03): Completed final toxicology studies and manufacturing clinical supplies with anticipated IND filing by end of 2025
- Older filing (2025-11-03): Phase 1 initiation anticipated in first half of 2026 with initial clinical data expected in second half of 2026
- Older filing (2025-11-03): Reference to iECURE, Inc. by full name
- Older filing (2025-11-03): iECURE presentations at September 2025 conferences in Kyoto, Japan and October 2025 conferences in Spain and Boston
- Older filing (2025-11-03): Previously reported clinical results showing complete clinical response at lowest dose level (1.3x10^13 GC/kg)
- Older filing (2025-11-03): OTC-HOPE data expected in first half of 2026
- Older filing (2025-11-03): Imugene September 2025 announcement of Phase 1b efficacy data with 81% overall response rate and seven complete responses and six partial responses
- Older filing (2025-11-03): Imugene October 28, 2025 announcement of first efficacy results from CAR T-naïve cohort (text cut off in older version)
- Reworded:
- Chronic Hepatitis B changed to chronic hepatitis B in newer filing (2026-05-05)
- ELIMINATE-B trial description changed from 'multiple ascending dose levels with three dose administrations per dose level' to focus on 'escalating dose levels as well as 8-week and 4-week dosing intervals' in newer filing
- PBGENE-HBV now described as 'first in vivo gene editing approach to prospectively employ repeat administrations of lipid nanoparticle (LNP)' in newer filing (2026-05-05)
- DMD treatment target changed from 'more than 60%' to 'approximately 60%' in newer filing (2026-05-05)
- Reference to 'synthetic, truncated dystrophin approaches' in older filing changed to 'synthetic, truncated microdystrophin approaches' in newer filing (2026-05-05)
- PBGENE-HBV program description expanded from eliminating 'cccDNA and inactivate integrated HBV DNA' to specifically state 'covalently closed circular DNA (cccDNA), the sole source of viral replication' in newer filing
- Notes:
- Text in older filing (2025-11-03) is truncated at end (Imugene section incomplete), limiting full comparison of final section
- Text in newer filing (2026-05-05) is also truncated at end (azer-cel section incomplete), limiting full comparison of final section
- Older filing references multiple clinical conferences and data presentations from September and October 2025, while newer filing references conferences and milestones from 2026, reflecting different reporting periods
Risk Factors
- Reworded:
- Changed 'Since inception' to 'Historically' in description of operating losses (filed 2026-05-05 vs filed 2025-11-03)
- Updated net loss period from 'nine months ended September 30, 2025' ($65.9 million) to 'three months ended March 31, 2026' ($18.4 million) (filed 2026-05-05)
- Updated accumulated deficit from '$548.3 million as of September 30, 2025' to '$546.6 million as of March 31, 2026' (filed 2026-05-05)
- Notes:
- Both filings appear truncated at the end of the 'We will need substantial additional funding' section, making full comparison of that section incomplete
- Page numbers differ (32 in newer filing vs 37 in older filing), indicating different document lengths overall
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for DTIL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DTIL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 611,832
- Reported value $3,365,078
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DTIL had 2,878,337 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DTIL had 10.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.48 days to cover at the same settlement.
- Reported short interest (shares) 2,878,337
- Short interest (% of shares outstanding) 10.4%
- Prior settlement (shares) 2,384,495
- Reported change 20.71%
- Days to cover (reported) 10.48
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Editas Medicine (NASDAQ: EDTA)
- CRISPR Therapeutics (NASDAQ: CRSP)
- Beam Therapeutics (NASDAQ: BEAM)
- Sangamo Therapeutics (NASDAQ: SGMO)
- Intellia Therapeutics (NASDAQ: NTLA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DTIL vs…
Frequently asked questions
What does PRECISION BIOSCIENCES INC (DTIL) do?
Precision BioSciences is a clinical-stage gene editing company that develops in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. ARCUS is a natural homing endonuclease that enables precise gene editing through insertion, excision, and elimination. The company currently has two lead clinical programs: PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, plus a partnered program with iECURE for OTC deficiency.
What sector is PRECISION BIOSCIENCES INC (DTIL) in?
PRECISION BIOSCIENCES INC (DTIL) is classified in the Health Care sector. Its industry is Gene editing / genome editing therapeutics. It trades on NASDAQ.
Who are PRECISION BIOSCIENCES INC's (DTIL) competitors?
Notable peers of PRECISION BIOSCIENCES INC (DTIL) include Editas Medicine (NASDAQ: EDTA), CRISPR Therapeutics (NASDAQ: CRSP), Beam Therapeutics (NASDAQ: BEAM), Sangamo Therapeutics (NASDAQ: SGMO) and Intellia Therapeutics (NASDAQ: NTLA). This peer set is informational only — not financial advice.
Is PRECISION BIOSCIENCES INC (DTIL) overbought or oversold right now?
PRECISION BIOSCIENCES INC (DTIL) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DTIL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.